Benefits of long-term oxygen therapy
====================================

Early reports on respiratory failure in patients with chronic obstructive pulmonary disease (COPD) suggested that oxygen therapy decreases pulmonary hypertension and red cell mass while simultaneously increasing exercise capacity ([@b28-copd-3-231]) In the 1980s, two landmark multicentre trials, the Nocturnal Oxygen Therapy Trial (NOTT) ([@b26-copd-3-231]) and the Medical Research Council (MRC) ([@b24-copd-3-231]) study, showed that long-term oxygen therapy (LTOT) was the sole treatment that improved survival in patients with COPD and chronic respiratory failure (CRF), and that these patients received oxygen for at least 18 hours/day ([Figure 1](#f1-copd-3-231){ref-type="fig"}). These findings were reaffirmed in later trials ([@b13-copd-3-231]; [@b44-copd-3-231]). [@b26-copd-3-231] and [@b24-copd-3-231] trials led to the establishment of criteria for oxygen therapy in almost every country in the developed world ([Table 1](#t1-copd-3-231){ref-type="table"}) ([@b35-copd-3-231]; [@b1-copd-3-231]; [@b15-copd-3-231]; [@b5-copd-3-231]; [@b32-copd-3-231]). There is also evidence that LTOT has benefits other than survival. These include stabilization of pulmonary arterial hypertension, fewer cardiac arrhythmias and electrocardiographic findings suggestive of myocardial ischemia, increased exercise capacity, an improvement in neuropsychiatric function and in health-related quality of life, and a reduction of exacerbations or hospitalizations ([@b41-copd-3-231]; [@b11-copd-3-231]; [@b23-copd-3-231]; [@b12-copd-3-231]; [@b6-copd-3-231]; [@b42-copd-3-231]; [@b33-copd-3-231]; [@b14-copd-3-231]). However, these clinical benefits depend on treatment compliance, the duration of the treatment, and adequate correction of hypoxemia ([@b19-copd-3-231]; [@b36-copd-3-231]; [@b29-copd-3-231]; [@b31-copd-3-231]; [@b8-copd-3-231]; [@b38-copd-3-231]).

Which patients can improve with LTOT?
=====================================

The NOTT and MRC studies demonstrated that LTOT improved survival in COPD with resting partial pressure of oxygen in arterial blood (PaO~2~) \<60 mmHg either with or without hypercapnia. The trial reported by [@b18-copd-3-231], however, found LTOT had no effect on survival in patients with COPD and moderate hypoxemia (56--65 mmHg). Does the lack of benefits on survival in some patients mean that not all these patients should be offered LTOT? Or should we analyze other benefits of LTOT rather than survival? From the results of many trials it is reasonable to hypothesize that LTOT may benefit COPD patients in different ways, such as in exercise capacity ([@b11-copd-3-231]; [@b23-copd-3-231]; [@b12-copd-3-231]), health-related quality of life ([@b14-copd-3-231]), exacerbations or hospitalizations ([@b6-copd-3-231]; [@b33-copd-3-231]). Therefore, as the recent National Heart, Lung, and Blood Institute (NHLBI) workshop proposed, we need to consider these other benefits in COPD patients independently from the increase in survival ([@b9-copd-3-231]).

How to prescribe LTOT?
======================

Supplemental oxygen should be included in the continuum of care along with cessation of smoking, pharmacological therapy, vaccination, attention to infectious exacerbations, and respiratory rehabilitation. Good coping skills, motivation, and a supportive family influence compliance with supplemental oxygen. Patients need to be able to meet the criteria for LTOT ([Table 1](#t1-copd-3-231){ref-type="table"}); they must be clinically stable, and should be receiving optimal pharmacological treatment prior to commencement. The oxygen flow should be titrated during the daytime with the patient awake and at rest. It is recommended to set the oxygen flow to achieve transcutaneus oxygen saturation (SaO~2~) ≥90%.

Are we assessing eligibility appropriately for LTOT?
====================================================

Before prescribing LTOT, arterial blood gas measurements should be performed at least twice to confirm the patient meets the criteria for this treatment. However, in clinical practice, LTOT is frequently prescribed in an unstable clinical situation or after a single assessment, as reported by several authors. [@b21-copd-3-231] found that 23 of 77 patients under LTOT since hospital discharge were no longer eligible at 3 months' follow up. More recently, in a randomized trial, Guyatt and colleagues (2005) affirmed that reassessment of applicants for LTOT identified an appreciable portion of initially eligible patients who were no longer eligible.

Should all COPD patients with criteria for LTOT be treated 24 hours/day?
========================================================================

Although different guidelines recommend LTOT for at least 18 hours/day, the combined data from the [@b26-copd-3-231] and [@b24-copd-3-231] studies indicate that the longer the oxygen-use, the greater the benefit. Careful observation of data in [Figure 1](#f1-copd-3-231){ref-type="fig"} reveals that patients who used oxygen 24 hours/day have higher survival than the other groups. Some studies have shown that COPD patients have severe desaturation during daily activities such as walking, eating, or washing ([@b37-copd-3-231]). The NOTT and MRC studies were developed before portable oxygen devices were in common use; liquid oxygen devices are now readily available in most developed countries. It may therefore be advisable to prescribe LTOT in the form of liquid oxygen and advice patients to use this therapy all day, especially during exercise. Trials investigating the benefits of 24-hour rather than 18-hour LTOT are needed.

Does the oxygen flow prescribed adequately correct saturacion of oxygen?
========================================================================

At rest
-------

According to COPD and LTOT treatment guidelines ([@b35-copd-3-231]; [@b1-copd-3-231]; [@b15-copd-3-231]; [@b5-copd-3-231]; [@b32-copd-3-231]) the oxygen flow should be titrated during the daytime when the patient is clinically stable and awake, using the same oxygen source as that received at home. It is recom- mended to set the oxygen flow to achieve SaO~2~ ≥90% using a pulse oximeter, taking an arterial blood gas sample to assure correct titration. An overnight pulse oximetry should be recorded during sleep to evaluate the correction in nocturnal SaO~2~.

From an international survey about LTOT prescription, [@b43-copd-3-231] showed that there were marked differences among countries as to how LTOT was prescribed. In many European countries patients are tested in supine rather than sitting position, the target SaO~2~ varies from 90% to 92%, and not all countries measure arterial blood gases or test SaO~2~ during sleep.

During exercise
---------------

There are no specific recommendations about oxygen prescription during exercise. Some guidelines advise using an effort test to assess the adequate oxygen flow to correct oxygen desaturation. To establish the appropriate oxygen flow it is recommended to test patients under increasing oxygen flow until SaO~2~ ≥90%. The most frequently used effort test is the 6-minute walking test (6Wt), which some authors have shown to be a reliable measurement. Comparing SaO~2~ during the 6WT with that of ambulatory pulsioximetry, [@b22-copd-3-231] showed that the 6WT is a good reflection of desaturation during daily activities measured by ambulatory pulse oximetry. These authors also demonstrated a good correlation between the two measurements when patients are breathing oxygen (p \< 0.01) ([Tables 2](#t2-copd-3-231){ref-type="table"} and [3](#t3-copd-3-231){ref-type="table"}).

[@b43-copd-3-231] international survey showed that most countries assess patients during exercise to achieve SaO~2~ ≥90%. However, ATS guidelines and some European countries recommend the resting flow rate should be increased by 1 l. min^−1^ or that the same flow rate as at rest should be used without testing the oxygen flow rate needed during exercise.

During sleep
------------

There are three ways to adjust the oxygen flow during sleep: maintaining the resting flow rate, increasing the resting flow rate by 1 or 2.l. min^−1^, or setting the flow rate according to continuous monitoring of SaO~2~ to maintain SaO~2~ ≥90%.

Using the resting flow rate, several studies ([@b31-copd-3-231]; [@b38-copd-3-231], [@b25-copd-3-231]) have found an inadequate correction in nocturnal SaO~2~ in a high, and variable percentage of patients (13%--48%). Various factors could explain these differences. Firstly, neither of the two first studies ([@b31-copd-3-231]; [@b38-copd-3-231]) excluded diseases associated to COPD, such as pulmonary restrictive disorders, that could produce nocturnal desaturation. Secondly, the presence of obstructive sleep apnea syndrome (OSAS) was not ruled out.

To prevent sleep desaturation, some guidelines recommend increasing the resting flow rate oxygen 1 or 2.l. min^−1^. In their international study, [@b43-copd-3-231] observed that in Canada and US there was a tendency to increase the oxygen flow rate during sleep, whereas in most European countries the tendency was either to maintain the same flow rate as that used during the day or to test patients individually.

Oxygen therapy can generate several potentially detrimental effects. The most relevant of these is hypercapnia, which is mediated by mechanisms such as hypoventilation, ventilation-perfusion redistribution, or the Haldane effect. Moreover, sleep itself generates ventilatory alterations that include a decrease in baseline metabolism, an increase in airway resistance, hypotonia of the respiratory pump, and decreased sensitivity of respiratory centers. In healthy individuals, these alterations generate only small changes in PaO~2~ or PaCO~2~ during the night, but in COPD patients they may cause severe hypoxemia and hypercapnia. In this population, physiopathologic phenomena such as greater hypoventilation due to a reduction in tidal volume, greater alterations in ventilation-perfusion distribution, associated OSAS and reduction of mucociliar clearance may also be key to increased hypercapnia and development of sleep hypoventilation (SH). [@b27-copd-3-231] and [@b38-copd-3-231] observed SH in a high percentage of COPD patients, 43% and 59%, respectively, and suggested the finding was likely due to the oxygen therapy. Increasing the resting flow rate by 1 or 2 l min^−1^ may therefore exacerbate hypoventilation. Our group recently conducted a study to evaluate changes in gas exchange. We increased the nocturnal flow rate by 1 liter and observed that this induced SH and respiratory acidosis in a significant number of patients who did not have SH when they received the same oxygen titration as during the day (34.2% vs. 23.7% of patients) ([Figures 2](#f2-copd-3-231){ref-type="fig"} and [3](#f3-copd-3-231){ref-type="fig"}) ([@b34-copd-3-231]). This finding further supports the hypothesis that oxygen can induce hypoventilation. [@b30-copd-3-231] had previously shown that a high oxygen flow rate in acute respiratory failure in COPD patients was the most frequent cause of hypercapnia and led to the need for noninvasive ventilation. Such results reinforce the need to evaluate and titrate the nocturnal oxygen flow individually, at least in hypercapnic COPD patients.

According to some guidelines, continuous monitoring of SaO~2~ should be performed to set the oxygen flow rate during sleep to maintain SaO~2~ ≥90% overnight. We consider arterial blood gases should be measured early in the morning to test for hypercapnia and respiratory acidosis. If patients present these findings then our advice is to test for the presence of OSAS. Once OSAS is ruled out, the best way to treat these patients with SH under oxygen therapy may be to use the Venturi mask or noninvasive ventilation. The subgroup of COPD patients who develop SH under oxygen therapy may be the only COPD candidates for whom domiciliary noninvasive ventilation therapy is recommended rather than LTOT.

What is the role of oxygen conservation systems on COPD patients undergoing LTOT?
=================================================================================

Oxygen conservation systems could optimize the benefit of LTOT in some patients. Such devices should only be used in patients who need low oxygen flow rates. Their effectiveness depends on the valve trigger, the patient's breathing rate, and the presence of nasal breathing.

Some studies have shown that conservation systems are effective at rest, during sleep and during exercise ([@b40-copd-3-231], [@b39-copd-3-231]; [@b3-copd-3-231]; [@b4-copd-3-231]; [@b10-copd-3-231]; [@b17-copd-3-231]; [@b16-copd-3-231]). [@b10-copd-3-231] showed that there were no differences in the ventilatory parameters when COPD patients used conventional or conservation systems for LTOT. Other studies, however, have shown that to maintain an adequate SaO~2~ in some patients it is necessary to increase the oxygen flow rate. Conservative systems have different characteristics. [@b2-copd-3-231] compared three different models of these systems and found that each model gave a different quantity of oxygen. These systems should be tested individually at rest and during exercise.

Recommendations for future research
===================================

The NHLBI workshop report ([@b9-copd-3-231]) recently reported a very interesting review about the current state of knowledge of LTOT and proposed topics for future research. The most relevant issues for study, according to the said paper, are the use of LTOT in COPD patients with moderate hypoxemia, the efficacy of LTOT in patients who desaturate during exercise and sleep, the optimal dosage of oxygen supplementation, and the compliance of LTOT.

Three considerations related to LTOT for COPD patients with moderate hypoxemia are yet to be addressed. The first of these is that the duration of treatment may need to be longer than 18 hours per day. Second, benefits other than survival should be considered, such as health-related quality of life, exercise capacity, or hospitalizations. Third, it is necessary to identify subgroups of COPD patients with moderate hypoxemia who can benefit from LTOT, such as patients with pulmonary hypertension, low body mass index, poor exercise capacity, frequent exacerbations, or co-morbid cardiac disease.

There is insufficient evidence that LTOT can provide benefits to patients with exercise desaturation. Nevertheless, it seems logical that episodic hypoxemia may itself have adverse consequences and increase effort dyspnoea. Very few studies have been performed to date regarding the role of oxygen therapy for COPD patients with sleep desaturation. We can hypothesize that oxygen therapy could increase survival by reducing the risk factors, especially cardiac events, produced by desaturation during sleep, and also increase the quality of sleep. From the NOTT and MRC studies it seems obvious that 24 hours/day will be much more beneficial for COPD patients than 18 hours/day, and that an adequately adjustment of oxygen flow at rest, during effort, and sleep will provide more benefits.

Finally, it is well known that compliance with LTOT is very poor in COPD patients. An important goal in the future therefore should be to develop patient education strategies regarding the use of LTOT and to improve oxygen therapy devices.

Based on these observations concerning LTOT, the NHLBI workshop ([@b9-copd-3-231]) proposed four trials to investigate the role of: (1) oxygen supplementation during ambulation; (2) continuous oxygen supplementation for moderate hypoxemia; (3) nocturnal oxygen treatment for desaturation during sleep; and (4) detailed, individualized prescriptions for LTOT supplementation. We would like to add a further topic, addressed to the prescription of LTOT in patients with diseases other than COPD, such as restrictive pulmonary diseases or cardiac diseases.

![Comparison of survival curves of NOTT and MRC studies. The poorest prognosis was in the MRC controls who received no oxygen. The best survival was in the NOTT patients who received oxygen for \>19 hours/day. Copyright © 1980, 1981. Modified with permission from \[NOTT\] [@b26-copd-3-231]. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Nocturnal Oxygen Therapy Trial Group. *Ann Inter Med*, 93:391--8; [@b24-copd-3-231]. Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Report of the Medical Research Council Working Party. *Lancet*, 1:681--5.\
**Abbreviations:** MRC, Medical Research Council; NIH, National Institutes of Health; NOTT, Nocturnal Oxygen Therapy Trial.](copd-3-231f1){#f1-copd-3-231}

![Evolution of PaCO~2~ ▪: oxygen flow titrated at daytime,▴: 1 litre increase in oxygen flow.\
**Note:** p \< 0.05 [@b34-copd-3-231].\
**Abbreviation:** PaCO~2~, partial pressure of oxygen in arterial blood.](copd-3-231f2){#f2-copd-3-231}

![Evolution of pH▪: oxygen flow titrated at daytime,▴: 1 litre increase in oxygen flow.\
**Note:** p \< 0.05 [@b34-copd-3-231].](copd-3-231f3){#f3-copd-3-231}

###### 

Indications for LTOT in COPD ([@b7-copd-3-231])

  UNITED STATES
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  PaO~2~ \<55 mmHg or SaO~2~ \< 88% (room air)
  PaO~2~ 56--59 mmHg or SaO~2~ 89%--90%, with (one or more)
  Pulmonary hypertension
  Evidence of cor pulmonale or edema due to heart failure
  Elevated hematocrit (\>56%)
  **UNITED KINGDOM**
  COPD (FEV~1~ \< 1.5 L, FVC \< 2.0 L), hypoxemia (PaO~2~ \< 55 mmHg), hypercapnia (PaCO~2~ \> 45 mmHg), and edema. Stability demonstrated over 3 weeksAs in 1 but without edema or PaCO~2~ \> 45 mmHg Palliative therapy may be prescribed
  **EUROPE**
  PaO~2~ \< 55 mmHg, steady-state COPDPaO~2~ 55--65 mmHg with (one or more)
  Pulmonary hypertension
  Evidence of cor pulmonale or edema due to heart failure
  Elevated hematocrit (\>56%)
  Restrictive disease with PaO~2~ \< 55 mmHg
  **AUSTRALIA**
  PaO~2~ \< 56 mmHg, COPD, Right ventricular hypertrophy, polycythemia, and edemaDesaturation \<90% on exerciseRefractory dyspnea associated with cardiac failure

**Abbreviations:** COPD, chronic obstructive pulmonary disease; FEV~1~, forced expiratory volume in one second; FVC, forced vital capacity; PaO~2~, partial pressure of oxygen in arterial blood; SaO~2~, oxygen saturation.

###### 

comparison of SaO**2** under liquid oxygen between the 6 minute walking test (6WT) and the ambulatory pulse oximetry (AP)

                    6WT       AP        \(p\)
  ----------------- --------- --------- -------
  SaO~2~ mean (%)   90 (3)    92 (2)    0.28
  CT90 (%)          53 (35)   22 (15)   0.47
  CT88 (%)          29 (33)   11 (11)   0.1
  CT85 (%)          8 (11)    6 (6)     0.6

**Abbreviations:** Mean SaO~2~, mean value of saturation of oxihemoglobin; CT90, percentage of time with SaO~2~ \<90%; CT88, percentage of time with SaO~2~ \<88%; CT85, percentage of time with SaO~2~ \<85% ([@b22-copd-3-231]).

###### 

Correlation of the SaO**2** values between the 6-minute walking test (6WT) and the ambulatory pulse oximetry (AP)

                    6WT       AP        r (p)
  ----------------- --------- --------- ---------------
  SaO~2~ mean (%)   84 (7)    89 (4)    0.7 (\<0.01)
  CT90 (%)          77 (34)   53 (32)   0.6 (\<0.01)
  CT88 (%)          56 (42)   35 (30)   0.51 (\<0.01)
  CT85 (%)          42 (44)   19 (23)   0.65 (\<0.01)

**Abbreviations:** Mean SaO~2~, mean value of saturation of oxihemoglobin; CT90, percentage of time with SaO~2~ \<90%; CT88, percentage of time with SaO~2~ \<88%; CT85, percentage of time with SaO~2~ \<85% ([@b22-copd-3-231]).
